Sapropterin dihydrochloride: A new drug and a new concept in the management of phenylketonuria

Drugs of Today

Volumn 46, Issue 8, 2010, Pages 589-600

  Trefz, Friedrich K ^a   Belanger Quintana A ^b  

^a Klinikum am Steinenberg   (Germany)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; PLACEBO; SAPROPTERIN; TETRAHYDROBIOPTERIN; 5,6,7,8-TETRAHYDROBIOPTERIN; BIOPTERIN; DRUG DERIVATIVE;

ABDOMINAL PAIN; ALLOSTERISM; AMINO ACID BLOOD LEVEL; BODY WEIGHT; COGNITION; CONTUSION; COUGHING; DIARRHEA; DIET RESTRICTION; DIETARY INTAKE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXPOSURE; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FACE DYSMORPHIA; FETAL ALCOHOL SYNDROME; FETUS OUTCOME; GENE MUTATION; GENOTYPE; HUMAN; HYPERPHENYLALANINEMIA; LOADING TEST; MENTAL DEFICIENCY; NONHUMAN; NOSE CONGESTION; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHENYLKETONURIA; PREVALENCE; PROTEIN STRUCTURE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; EVIDENCE BASED MEDICINE; GENETICS; METABOLISM; ORAL DRUG ADMINISTRATION; TABLET; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BIOPTERIN; EVIDENCE-BASED MEDICINE; HUMANS; PHENYLALANINE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS; TABLETS; TREATMENT OUTCOME;

EID: 79952113390     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.8.1509557     Document Type: Review

References (70)

1. Følling, A. Utskillelse av fenylpyrodruesyre i urinen som stoffskifteanomali i forbindelse med im becilletet. Nord Med Tidskr 1934, 8: 1054-9.
2. Centerwall, S.A., Centerwall, W.R. The discovery of phenylketonuria: The story of a young couple, two retarded children, and a scientist. Pediatrics 2000, 105(1 pt. 1): 89-103.
3. Bickel, H., Gerrard, J., Hickmans, E.M. Influence of phenylalanine intake on phenylketonuria. Lancet 1953, 265(6790): 812-3.
4. Guthrie, R., Susi, A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963, 32: 338-43.
5. The changing moral focus of newborn screening: An ethical analysis by the President's Council on Bioethics. The President's Council on Bioethics, Washington, D.C., December 2008. Appendix. Newborn Screening: An International Survey Available at http://bioethics.george-town.edu/pcbe/reports/newbon- screening/index.html (accessed May 2010).
6. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and management, October 16-18, 2000. Pediatrics 2001, 108(4): 972-82.
7. van Spronsen, F.J., Burgard, P. The truth of treating patients with phenylketonuria after childhood: The need for a new guideline. J Inherit Metab Dis 2008, 31(6): 673-9.
8. Brumm, V.L., Bilder, D., Waisbren, S.E. Psychiatric symptoms and disorders in phenylketonuria. Mol Genet Metab 2010, 99(Suppl. 1): S59-63.
9. Kuvan® European Summary of Product Characteristics. Available at http://www.emc.medicines.org.uk/medicine/21362/SPC/Kuvan+100+mg+soluble+tablets/ (accessed January 2010).
10. Kuvan® full US Prescribing Information. Available at http://www.kuvan.com/Downloads/KuvanPI.pdf (accessed March 2010).
11. Williams, R.A., Mamotte, C.D., Burnett, J.R. Phenylketonuria: An inborn error of phenylalanine metabolism. Clin Biochem Rev 2008, 29(1): 31-41.
12. Loeber, J.G. Neonatal screening in Europe; The situation in 2004. J Inherit Metab Dis 2007, 30(4): 430-8.
13. Ozalp, I., Coskun, T., Tokatli, A. et al. Newborn PKU screening in Turkey: At present and organization for future. Turk J Pediatr 2001, 43(2): 97-101. (Pubitemid 33688219)
14. Zschocke, J., Mallory, J.P., Eiken, H.G. et al. Phenylketonuria and the peoples of Northern Ireland. Hum Genet 1997, 100(2): 189-94.
15. Borrajo, G.J. Newborn screening in Latin America at the beginning of the 21st century. J Inherit Metab Dis 2007, 30(4): 466-81. (Pubitemid 47377042)
16. Zhan, J.Y., Qin, Y.F., Zhao, Z.Y. Neonatal screening for congenital hypothyroidism and phenylketonuria in China. World J Pediatr 2009, 5(2): 136-9.
17. Jiang, J., Ma, X., Huang, X., Pei, X., Liu, H., Tan, Z., Zhu, L. A survey for the incidence of phenylketonuria in Guangdong, China. Southeast Asian J Trop Med Public Health 2003, 34 Suppl 3: 185.
18. Pangkanon, S., Charoensiriwatana, W., Janejai, N., Boonwanich, W., Chaisomchit, S. Detection of phenylketonuria by the newborn screening program in Thailand. Southeast Asian J Trop Med Public Health 2009, 40(3): 525-9.
19. Charoensiriwatana, W., Janejai, N., Boonwanich, W., Krasao, P., Chaisomchit, S., Waiyasilp, S. Neonatal screening program in Thailand. Southeast Asian J Trop Med Public Health 2003, 34(Suppl. 3): 94-100.
20. Aoki, K. Long term follow-up of patients with inborn errors of metabolism detected by the newborn screening program in Japan. Southeast Asian J Trop Med Public Health 2003, 34(Suppl. 3): 19-23.
21. Lindner, M. Treatment of phenylketonuria variants: European recommendations. In: PKU and BH4: Advances in Phenylketonuria and Tetrahydrobiopterin. N. Blau (Ed.). SPS Verlagsgesellschaft: Heilbronn 2006, 180-7.
22. Marsden, D., Levy, H. Classification of PKU. In: PKU and BH4: Advances in Phenylketonuria and Tetrahydrobiopterin. N. Blau (Ed.). SPS Verlagsgesellschaft: Heilbronn 2006, 92-103.
23. Thöny, B. Tetrahydrobiopterin and its functions. In: PKU and BH4: Advances in Phenylketonuria and Tetrahydrobiopterin. N. Blau (Ed.). SPS Verlagsgesellschaft: Heilbronn 2006, 503-55.
24. Blau, N., Bonafe, L., Blaskovics, M.E. Disorders of phenylalanine and tetrahydrobiopterin metabolism. In: Physician's Guide to the Laboratory Diagnosis of Metabolic Diseases, 2nd ed. N. Blau, M. Duran, M.E. Blaskovics, K.M. Gibson (Eds.). Springer-Verlag: Heidelberg 2003, 89-106.
25. Phenylalanine Hydroxylase. Online Mendelian Inheritance in Man database. #612349. Available at http://www.ncbi.nlm.nih.gov/omim (accessed March 2010).
26. Scriver, C.R., Waters, P.J., Sarkissian, C. et al. PAHdb: A locus-specific knowledgebase. Hum Mutat 2000, 15(1): 99-104.
27. Guttler, F., Ledley, F.D., Lidsky, A.S., DiLella, A.G., Sullivan, S.E., Woo, S.L.C. Correlation between polymorphic DNA haplotypes at the phenylalanine hydroxylase focus ond clinical phenotypes of phenylketonuria. J Pediatr 1987, 110(1): 68-71. (Pubitemid 17211884)
28. Kayaalp, E., Treacy, E., Waters, P.J., Byck, S., Nowacki, P., Scriver, C.R. Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: A metanalysis of genotype-phenotype correlations. Am J Hum Genet 1997, 61(6): 1309-17. (Pubitemid 28046907)
29. Guldberg, P., Rey, F., Zschocke, J. et al. A European multicenter study of phenylalanine hydroxylase deficiency: Classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am J Hum Genet 1998, 63(1): 71-9. (Pubitemid 30428320)
30. Trefz, F.K., Burgard, P., König, T. et al. Genotype-phenotype correlations in phenylketonuria. Clin Chim Acta 1993, 217(1): 15-21.
31. Waters, P.J., Parniak, M.A., Nowacki, P., Scriver, C.R. In vitro expression analysis of mutations in human and rat phenylalanine hydroxylase: Exploring molecular causes of hyperphenylalaninemia. Hum Mutat 1998, 11(11): 4-17.
32. Zurfluh, M.R., Zschocke, J., Lindner, M. et al. Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Hum Mutat 2008; 29(1): 167-75.
33. Desviat, L.R., Pérez, B., Gámez, A. et al. Genetic and phenotypic aspects of phenylalanine hydroxylase deficiency in Spain: Molecular survey by regions. Eur J Hum Genet 1999, 7(3): 386-92. (Pubitemid 29213746)
34. Kure, S., Hou, D.C., Ohura, T. et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 1999, 135(3): 375-8. (Pubitemid 30180515)
35. Bernegger, C., Blau, N.. High frequency of tetrahydrobiopterin- responsiveness among hyperphenylalaninemias: A study of 1919 patients observed from 1988 to 2002. Mol Genet Metab 2002, 77(4): 304-13.
36. Leuzzi, V., Carducci, C., Carducci, C. et al. The spectrum of phenylalanine variations under tetrahydrobiopterin load in subjects affected by phenylalanine hydroxylase deficiency. J Inherit Metab Dis 2006, 29(1): 38-46.
37. Mitchell, J.J., Wilcken, B., Alexander, I. et al. Tetrahydrobiopterin- responsive phenylketonuria: The New South Wales experience. Mol Genet Metab 2005, 86(Suppl. 1): S81-5.
38. Muntau, A.C., Röschinger, W., Habich, M. et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med 2002, 347(26): 2122-32. (Pubitemid 36015124)
39. Burton, B.K., Grange, D.K., Milanowski, A. et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): A phase II, multicentre, open-label, screening study. J Inherit Metab Dis 2007, 30(5): 700-7. (Pubitemid 47559882)
40. Nielsen, J.B, Nielsen, K.E., Güttler, F. Tetrahydrobiopterin responsiveness after extended loading test of 12 Danish PKU patients with the Y414C mutation. J Inherit Metab Dis 2010, 33(1): 9-16.
41. Fiege, B., Blau, N. Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria. J Pediatr 2007, 150(6): 627-30. (Pubitemid 46755809)
42. Blau, N., Bélanger-Quintana, A., Demirkol, M. et al. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol Genet Metab 2009, 96(4): 158-63.
43. Lindner, M., Gramer, C., Garbade, S.F., Burgard, P. Blood phenylalanine concentrations in patients with PAH-deficient hyperphenylalaninaemia off diet without and with three different single oral doses of tetrahydrobiopterin: Assessing responsiveness in a model of statistical process control. J Inherit Metab Dis 2009, 32(4): 514-22.
44. Karacic, I., Meili, D., Samavka, V. et al. Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency. Mol Genet Metab 2009, 97(3): 165-71.
45. Wang, L., Surendran, S., Michals-Matalon, K. et al. Mutations in the regulatory domain of phenylalanine hydroxylase and response to tetrahydrobiopterin. Genet Test 2007, 11(2): 174-8. (Pubitemid 47041936)
46. Trefz, F.K., Scheible, D., Götz, H., Frauendienst-Egger, G. Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria. J Inherit Metab Dis 2009, 32(1): 22-6.
47. Martinez, A., Calvo, A.C., Teigen, K., Pey, A.L. Rescuing proteins of low kinetic stability by chaperones and natural ligands phenylketonuria, a case study. Prog Mol Biol Transi Sci 2008, 83: 89-134.
48. Gersting, S.W., Kemter, K.F., Staudigl, M. et al. Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am J Hum Genet 2008, 83(1): 5-17.
49. Erlandsen, H., Pey, A.L., Gámez, A. et al. Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci USA 2004, 101(48): 16903-8. (Pubitemid 39601336)
50. Gersting, S.W., Lagler, F.B., Eichinger, A. et al. Pah(enu1) is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo. Hum Mol Genet 2010, 19(10): 2039-49.
51. Feiltet, F., Clarke, L., Meli, C. et al. Pharmacokinetics of sapropterin in patients with phenylketonuria. Clin Pharmacokinet 2008, 47(12): 817-25.
52. Musson, D.G., Kramer, W.G., Foehr, E.D., Bieberdorf, F.A., Hornfeldt, C.S., Kim, S.S., Dorenbaum, A. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: A randomized, open-label, crossover study in healthy adults. Clin Ther 2010, 32(1): 338-46.
53. Blau, N. Defining tetrahydrobiopterin (BH4)-responsiveness in PKU. J Inherit Metab Dis 2008, 31(1): 2-3.
54. Levy, H.L., Milanowski, A., Chakrapani, A. et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: A phase III randomised placebo-controlled study. Lancet 2007, 370(9586): 504-10. (Pubitemid 47212372)
55. Trefz, F.K., Burton, B.K., Longo, N. et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: A phase III, randomized, double-blind, placebo-controlled study. J Pediatr 2009, 154(5): 700-7.
56. Lee, P., Treacy, E.P., Crombez, E. et al. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet A. 2008, 146A(22): 2851-9.
57. Fernhoff, P.M., Burton, B.K., Nowacka, M., Hennermann, J.B., Kakkis, E., Dorenbaum, A. PKU-008: A long-term, open-label study of sapropterin dihydrochloride (Kuvan®) in PKU subjects. American College of Medical Genetics 2009, Abst 190 (available from http://submissions.miracd.com/acmg/ ContentInfo.aspx?conID=1135, accessed February 2010).
58. Champigneulle, A., Gasteyger, C., Bettiol, E., Villemagne, H., Nespithal, K., Bassett, R. The Kuvan® Adult Maternal Pediatric European Registry (KAMPER): A long-term observational study of patients with hyperphenylalaninemia treated with Kuvan®. 11th International Congress on Inborn Errors of Metabolism, (San Diego) 2009 Abst 195.
59. Kuvan Adult Maternal Pediatric European Registry (KAMPER), http://www/clinicaltrials.govidentifierNCT01016392.
60. Phenylketonuria Demographic, Outcomes, and Safety Registry (PKUDOS), http://www/clinicaltrials.govidentifierNCT00778206.
61. Wasserstein, M., Burton, B., Cederbaum, S. et al. Results of a phase II, multicenter, open-label study of sapropterin dihydrochloride in subjects with hyperphenylalaninemia related to primary BH4 deficiency. 58th Annu Meet Am Soc Hum Genet (November 11-15, Philadelphia) 2008, Poster 774T.
62. Blau, N., Burgard, P. Disorders of phenylalanine and tetrahydrobiopterin metabolism. In: Physician's Guide to the Treatment and Follow-up of Metabolic Diseases. N. Blau, G.F. Hoffmann, J. Leonard, J.T.R. Clarke (Eds.). Springer: Berlin 2006, 25-34.
63. Ponzone, A., Ferraris, S., Baglieri, S., Spada, M. Treatment of tetrahydrobiopterin deficiencies. In PKU and BH4: Advances in Phenylketonuria and Tetrahydrobiopterin. N. Blau (Ed.). SPS Verlagsgesellschaft: Heilbronn 2006, 612-37.
64. Singh, R.H., Jurecki, E., Rohr, F. Recommendations for personalized dietary adjustments based on patient response to tetrahydrobiopterin (BH4) in phenylketonuria. Top Clin Nutr 2008, 23(2): 149-57.
65. Waisbren, S.E., Noel, K., Fahrbach, K. et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: A systematic literature review and meta-analysis. Mol Genet Metab 2007, 92(1-2): 63-70. (Pubitemid 47361886)
66. Anastasoaie, V., Kurzius, L., Forbes, P., Waisbren, S. Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Mol Genet Metab 2008, 95(1-2): 17-20.
67. Gassio, R., Vilaseca, R., Lambruschini, N., Boix, C., Fusté, M.E., Campistol, J. Cognitive functions in patients with phenylketonuria in long-term treatment with tetrahydrobiopterin. Mol Genet Metab 2010, 99(Suppl. 1): S75-8.
68. Grange, D.K., Christ, S.E., White, D. Neuropsychological function in individuals with phenylketonuria treated with Kuvan®. International Congress of Inborn Errors of Metabolism (August 29-September 2, San Diego) 2009, Abst 216.
69. Gassió, R., Campistol, J., Vilaseca, M.A., Lambruschini, N., Cambra, F.J., Fusté, E. Do adult patients with phenylketonuria improve their quality of life after introduction/ resumption of a phenylalanine- restricted diet? Acta Paediatr 2003, 92(12): 1474-8.
70. Costa, L.G., Guizzetti, M., Burry, M., Oberdoerster, J. Developmental neurotoxicity: Do similar phenotypes indicate a common mode of action? A comparison of fetal alcohol syndrome, toluene embryopathy and maternal phenylketonuria. Toxicol Lett 2002, 127(1-3): 197-205. (Pubitemid 34615511)